CAS 1228013-15-7

Pyrazino[2,3-b]pyrazin-2(1H)-one, 1-ethyl-3,4-dihydro-7-[2-methyl-6-(1H-1,2,4-triazol-5-yl)-3-pyridinyl]-

CAS: 1228013-15-7

Formula: C₁₆H₁₆N₈O

Purity: 98%

Color and Shape: Solid

Molecular weight: 336.3512

Ref: IN-DA000JHZ

1-Ethyl-7-(2-Methyl-6-(1H-1,2,4-Triazol-5-Yl)Pyridin-3-Yl)-3,4-Dihydropyrazino[2,3-B]Pyrazin-2(1H)-One

CAS: 1228013-15-7

1-Ethyl-7-(2-Methyl-6-(1H-1,2,4-Triazol-5-Yl)Pyridin-3-Yl)-3,4-Dihydropyrazino[2,3-B]Pyrazin-2(1H)-One

Formula: C₁₆H₁₆N₈O

Purity: >98%

Molecular weight: 336.35

Ref: 54-OR1024345

CC-115

CAS: 1228013-15-7

CC-115

Formula: C₁₆H₁₆N₈O

Purity: ≥80%

Molecular weight: 336.35

Ref: 54-BUP09891

CC-115

CAS: 1228013-15-7

CC-115 is a inhibitor of mTOR/DNA-PK (IC50= 21/ 13 nM).

Formula: C₁₆H₁₆N₈O

Purity: 86.79% - 99.01%

Color and Shape: Solid

Molecular weight: 336.35

Ref: TM-T3541

CC-115

CAS: 1228013-15-7

1-Ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one

Formula: C₁₆H₁₆N₈O

Purity: 98+%

Molecular weight: 336.35

Ref: IN-DG630024

CC-115

CAS: 1228013-15-7

CC-115 is a small molecule that inhibits transcriptional regulation. It binds ATP-binding cassette transporters and blocks the export of fatty acids from the cell, which leads to increased levels of intracellular fatty acids and autophagy. CC-115 has shown efficacy in prostate cancer treatment, as well as squamous carcinoma. This drug has a potent inhibitory effect on gene expression and is currently undergoing clinical trials for use in high-risk disease.

Formula: C₁₆H₁₆N₈O

Purity: Min. 95%

Molecular weight: 336.35 g/mol

Ref: 3D-DZB01315